Total medical devices industry cross border M&A deals worth $2.2bn were announced in Europe in Q2 2022, led by ResMed’s $1bn acquisition of MediFox DAN Group, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 1312.3% over the previous quarter and a rise of 16.1% when compared with the last four-quarter average of $1.86bn.
Europe held an 80.30% share of the global medical devices industry cross border M&A deal value that totalled $2.69bn in Q2 2022. With a 66.17% share and deals worth $1.78bn, Germany was the top country in Europe’s cross border M&A deal value across medical devices industry.
In terms of deal activity, Europe recorded 36 cross border deals during Q2 2022, marking a decrease of 21.74% over the previous quarter and a rise of 17.07% over the last four-quarter average. Germany recorded nine deals during the quarter.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEurope medical devices industry cross border M&A deals in Q2 2022: Top deals
The top five medical devices industry cross border M&A deals accounted for 89.9% of the overall value during Q2 2022.
The combined value of the top five cross border M&A deals stood at $1.94bn, against the overall value of $2.2bn recorded for the quarter.
The top five medical devices industry cross border deals of Q2 2022 tracked by GlobalData were:
1) ResMed $1bn acquisition deal with MediFox DAN Group
2) The $541.63m acquisition of Phenox by Wallaby Medical
3) Integer $141.73m acquisition deal with Aran Biomedical
4) The $138.06m acquisition of SunshineSmile by Straumann
5) Cochlear $122.03m acquisition deal with Oticon Medical
